Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
Patients (Stage 1):
- Adults aged 18 or older
- Able to understand and follow the study procedures for the full duration of the study
- Able to understand and willing to sign a written consent form
- Able to speak, read, and understand English
- Has a confirmed diagnosis of locally advanced, metastatic, or castration-resistant prostate cancer, documented in medical records
- Has an upcoming appointment with a blood cancer or oncology specialist where genetic testing or targeted treatment is expected to be discussed
Patients (Stage 2):
- Took part in Stage 1 of the study
- Has already completed genetic testing (either from blood/saliva or from the tumour) for prostate cancer
- Able to understand and follow the study procedures for the full duration of the study
Patients (Stage 3):
- Adults aged 18 or older
- Able to understand and follow the study procedures for the full duration of the study
- Able to understand and willing to sign a written consent form
- Able to speak, read, and understand English
- Has a confirmed diagnosis of high-risk, very high-risk, locally advanced, metastatic, or castration-resistant prostate cancer, documented in medical records
- Has an upcoming appointment with a blood cancer or oncology specialist where germline (hereditary) genetic testing is expected to be discussed
Caregivers (Stage 1 & Stage 3):
- Adults aged 18 or older
- Named by a patient participant as someone involved in that patient's care, and willing to take part in interviews
- Able to give verbal consent
- Able to speak and understand English
Caregivers (Stage 2):
- Took part in Stage 1 of the study
- Is a partner, family member, or friend identified by a Stage 2 patient participant as their caregiver
Healthcare providers (Stage 1):
- A specialist doctor or nurse practitioner in blood cancers/oncology or genetics (clinical fellows past their first year are also eligible)
- Has discussed hereditary genetic testing, tumour genetic testing, or targeted therapy with a qualifying prostate cancer patient at the San Francisco VA Health Care System (SFVAHCS) within the past 90 days
- Able to provide consent by email
Healthcare providers (Stage 2 – SFVAHCS):
- Took part in Stage 1
- Is a medical oncology doctor who has discussed genetic testing or targeted therapy with an advanced prostate cancer patient within the past 30 days, OR a genetics doctor who has done so within the past 90 days
Healthcare providers (Stage 2 – Non-SFVAHCS):
- Is a lead investigator at a Precision Oncology Program for Cancer of the Prostate (POPCaP) site, OR a medical oncology doctor who has discussed genetic testing or targeted therapy with an advanced prostate cancer patient within the past 30 days, OR a genetics doctor who has done so within the past 90 days (confirm with trial site)
- Note: Clinical fellows are not eligible for the non-SFVAHCS provider group
- Able to understand and follow the study procedures for the full duration of the study
Healthcare providers (Stage 3):
- A doctor (MD) at SFVAHCS trained in medical oncology, or currently completing a clinical fellowship in that area
- Has discussed hereditary genetic testing for prostate cancer with an SFVAHCS patient within the past year, or plans to do so
- Able to provide verbal consent
Who may not be able to join:
Patients (Stage 1):
- People who are undergoing genetic testing and have already received their genetic test results before joining the study
Patients (Stage 3):
- People who have previously had hereditary (germline) genetic testing
- People who already took part in Stage 1 of the study specifically for germline testing
Caregivers and providers (all stages):
- People who do not meet the inclusion criteria listed above for their relevant group and stage
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Daniel Kwon, MD, University of California, San Francisco
Phone: 877-827-3222
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Mean score on the Decisional Conflict Scale (DCS) (Stage 1); Proportion of participants with a total score of >37.5 on the DCS (Stage 1); Proportion of participants enrolled (Stage 3); Proportion of participants providing reason for not enrolling (Stage 3)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.